ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.60
-0.34%
US Tech 100
17,650.00
0.05%
S&P 500
5,222.68
0.16%
US Dollar vs CAD
1.36785
0.00%
Bitcoin
60,593.58
-0.33%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Sanofi (SAN)

  7. Sanofi (SAN) News

SAN

Sanofi (SAN)

Sanofi
Date:
Sort by:
 Showing the most relevant articles for your search:EU:SAN
DateTimeSourceHeadlineSymbolCompany
05/10/20241:00AMGlobeNewswire Inc.Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccinesEU:SANSanofi
05/10/20241:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19EU:SANSanofi
05/10/20241:00AMGlobeNewswire Inc.Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccinesEU:SANSanofi
05/02/202412:00AMGlobeNewswire Inc.Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizationsEU:SANSanofi
05/02/202412:00AMGlobeNewswire Inc.Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizationsEU:SANSanofi
04/30/202411:00AMGlobeNewswire Inc.Press Release: Annual General Meeting of April 30, 2024EU:SANSanofi
04/30/202411:00AMGlobeNewswire Inc.Press Release: Annual General Meeting of April 30, 2024EU:SANSanofi
04/30/202411:00AMGlobeNewswire Inc.Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024EU:SANSanofi
04/25/202412:30AMGlobeNewswire Inc.Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidanceEU:SANSanofi
04/25/202412:30AMGlobeNewswire Inc.Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancementsEU:SANSanofi
04/23/202412:00AMGlobeNewswire Inc.Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaEU:SANSanofi
04/23/202412:00AMGlobeNewswire Inc.Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaEU:SANSanofi
04/23/202412:00AMGlobeNewswire Inc.Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaireEU:SANSanofi
04/17/202412:00AMGlobeNewswire Inc.Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisEU:SANSanofi
04/17/202412:00AMGlobeNewswire Inc.Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisEU:SANSanofi
04/17/202412:00AMGlobeNewswire Inc.Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaquesEU:SANSanofi
04/12/20241:05PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mars 2024EU:SANSanofi
04/12/20241:05PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - March 2024EU:SANSanofi
04/08/202411:00AMGlobeNewswire Inc.Sanofi - AGM 30.04.2024 - Mise à disposition des documents préparatoiresEU:SANSanofi
04/08/202411:00AMGlobeNewswire Inc.Sanofi - AGM 30.04.2024 - Availability of Preparatory documentsEU:SANSanofi
03/22/20241:30AMGlobeNewswire Inc.Press Release: Availability of the Q1 2024 Memorandum for modelling purposesEU:SANSanofi
03/22/20241:30AMGlobeNewswire Inc.Press Release: Availability of the Q1 2024 Memorandum for modelling purposesEU:SANSanofi
03/22/20241:30AMGlobeNewswire Inc.Communiqué de presse : Mise en ligne du document «Q1 2024 Memorandum for modelling purposes»EU:SANSanofi
03/15/20242:04PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - February 2024EU:SANSanofi
03/15/20242:04PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - FEVRIER 2024EU:SANSanofi
03/11/20241:00AMGlobeNewswire Inc.Communiqué de presse : De nouveaux résultats de phase II relatifs à l’amlitelimab confortent son potentiel de meilleur médicament de sa catégorie en termes de maintien de la réponse dans le traitement de la dermatite atopiqueEU:SANSanofi
03/11/20241:00AMGlobeNewswire Inc.Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitisEU:SANSanofi
03/11/20241:00AMGlobeNewswire Inc.Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitisEU:SANSanofi
02/24/20248:51AMGlobeNewswire Inc.Communiqué : Résultats de phase II montrent que le rilzabrutinib permet de réduire rapidement la sévérité des démangeaisons causées par l’urticaire chronique spontanée et d’améliorer significativement l’activité de la maladie chez l’adulEU:SANSanofi
02/24/20248:51AMGlobeNewswire Inc.Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticariaEU:SANSanofi
 Showing the most relevant articles for your search:EU:SAN

Your Recent History

ASX
ANZQOJ
HUOB
XRTETH
Robonomics
NASDAQ
AAZXCXX
Bmo Harris Bank Na Point...
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved